Non-reproductive tissues and cells
|
|
|
- Candice Parrish
- 5 years ago
- Views:
Transcription
1 Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding and not recommended on national level Non-reproductive tissues and cells VIRAL HIV 1 and HIV 2 Hepatitis B Hepatitis C HTLV-1 HTLV-2 Anti-HIV 1 YES N/A all all Anti-HIV 2 YES N/A all all HIV 1p24 HIV NAT YES N/A living donor HPCs; for living donor of tissues if serology is not days HBs Ag YES N/A all all Anti-HBc YES N/A all all Anti - HBs HBV NAT YES N/A living donor HPCs; for living tissue donor if serology is not days ; all tissues from living donors ; all tissues from living donors Anti-HCV YES N/A all all HCV NAT YES N/A living donor HPCs; for living tissue donor if serology is not days ; all tissues from living donors Anti-HTLV-1 YES N/A HTLV - 1 testing is all carried out only on donors with identified risk HTLV-1 NAT Anti-HTLV-2 YES N/A HTLV - 2 testing is all carried out only on donors with identified risk In some regions (e.g. Toscana and Veneto) the NAT test in living donors of tissues is always performed even if serology has been days. In some regions Anti - HBs maybe performed if anti (e.g.toscana and - HBc results are positive Veneto) the NAT test in living donors of tissues is always performed even if serology has been repeated after 180 days. In some regions (e.g. Toscana and Veneto) the NAT test in living donors of tissues is always performed even if serology has been 1 of 6 1.N-REPRODUCTIVE T&C 30/06/2016
2 Chikungunya virus HTLV-2 NAT YES N/A all all All donors that have been in risky Cytomegalovirus Anti-CHIKV CHIKV NAT Anti-CMV YES YES IBMDR Standard - living and cadaveric donors areas 28 days before or are syntomatic are excluded without further testing. The testing is /english-version/ibmdrmanual-of-operation for HPCs. For tissues: Italian guideline on quality and safety of tissues - july HPCs, skin, cardiac valves, vessels, amniotic membrane According to the National guidelines on tissues ( t/imgs/c_17_normativa_27_allega to.pdf) the NAT test has to be performed if anti -CMV IgM results are positive. CMV NAT Dengue Virus Anti-DENV YES N/A all all NAT Ebola Virus NAT YES N/A all all Anti-EBV YES N/A all all Hepatitis E Human Parvovirus B19 Herpes simplex virus Epstein-Barr virus According to the Ministerial Decree West Nile Virus PARASITIC WNV minipool NAT WNV ID NAT YES N/A testing is carried out only on donors with identified risk HPCs and bone only if frozen Babesiosis Leishmaniasis Malaria According to the Ministerial Decree Plasmodium sp. Ab YES N/A testing is carried out only on donors with identified risk all o+legislativo ) malaria testing has to be performed All donors that have been in risky areas or are symptomatic are excluded. All the other donors must be tested. All donors that have been in risky areas or are symptomatic are excluded. All the other donors 2 of 6 1.N-REPRODUCTIVE T&C 30/06/2016
3 Plasmodium sp. Ag Plasmodium sp. Ag - rapid test Plasmodium sp. NAT IgM on amniotic membrane donors Anti-Toxoplasma gondii YES YES IBMDR Standard - /english-version/ibmdrmanual-of-operation for HPCs. all donors all BACTERIAL Blood cultures YES Jacie Standard - wer?a=v&pid=sites&srcid=am FjaWUub3JnfGphY2llfGd4OjM 2Mzc5YzZmYTk0YmYzNzY depending on the donor's history and the characteristics of the tissues Toxoplasmosis According to the Ministerial Decree o+legislativo ) and the national guidelines on tissues ( t/imgs/c_17_normativa_27_allega to.pdf) toxoplasmosis testing has Trypanosomiasis to be performed on all amniotic membrane donors and for the According to the Ministerial Decree Anti-Trypanosoma cruzi YES N/A testing is carried out all only in donors with identified risk o+legislativo ) Trypanosoma testing has to be performed depending on the Treponema pallidum YES N/A all all (Syphilis) Anti-T. pallidum YES N/A all donors all T. pallidum NAT Chlamydia trachomatis Neisseria gonorrhoeae Brucellosis Tuberculosis Q-fever FUNGI specify technique YES Jacie Standard - m/viewer?a=v&pid=sit es&srcid=amfjawuub3 JnfGphY2llfGd4OjM2M zc5yzzmytk0ymyznzy 3 of 6 1.N-REPRODUCTIVE T&C 30/06/2016
4 Transmissible spongiform encephalopathies Other Tests ABO blood group testing ABO typing YES National laws: legge 219/2005 and DM ( ionalesangue.it/pagine /normativa-000) For HPCs: donors that have performed surgery or transfusion between 1980 to 1996 in UK are excluded For the other tissues it's not required RhD blood group testing RhD typing YES National laws: legge 219/2005 and DM ( ionalesangue.it/pagine /normativa-000) For the other tissues it's not required HLA testing For the other tissues it's not required HLA Ab HLA Ag HLA gene YES YES National laws: legge 219/2005 and DM ( ionalesangue.it/pagine /normativa-000) Genetic testing, please specify condition The type of techniques depends from what kind of infection/disease you suspect or you are looking for. The techniques are detailed in the IBMDR Standards YES YES IBMDR Standard - /english-version/ibmdrmanual-of-operation for HPCs. HPCs Cord Blood and PBSC In case of relevant medical testing or anamnestic history of hemoglobinopaties or of coagulation defects 4 of 6 1.N-REPRODUCTIVE T&C 30/06/2016
5 Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding and not recommended on national level Tested pathogen Donor test/ technique Legally binding Recommended on national level VIRAL HIV 1 and HIV 2 Hepatitis B Hepatitis C HTLV-1 Reproductive tissues and cells Recommending authority/ association Circumstances for application Donor profile Tissue/cell type Comments Anti-HIV 1 YES N/A partner donor gametes Anti-HIV 2 YES N/A partner donor gametes HIV 1p24 HIV NAT HBs Ag YES N/A partner donor gametes Anti-HBc YES N/A partner donor gametes Anti - HBs HBV NAT Anti-HCV YES N/A partner donor gametes HCV NAT YES N/A partner donor gametes Anti-HTLV-1 YES N/A Anti-HTLV 1 is mandatory for donors living in or coming from areas with high prevalence of HTLV or whose sexual partners or parents live or originate from areas with high prevalence of HTLV-1 all General note: all the information that is given for reproductive T&C refers exclusively to partner donation. Italy has introduced only recently the heterologous donation HTLV-2 Chikungunya virus Cytomegalovirus Ebola Virus Epstein-Barr virus Hepatitis E Human Parvovirus B19 Herpes simplex virus HTLV-1 NAT YES N/A partner donor gametes Anti-HTLV-2 HTLV-2 NAT 5 of 6 2.REPRODUCTIVE T&C 30/06/2016
6 Tested pathogen Donor test/ technique Legally binding Recommended on national level West Nile Virus PARASITIC Babesiosis Leishmaniasis Malaria Toxoplasmosis Trypanosomiasis BACTERIAL Treponema pallidum (Syphilis) Chlamydia trachomatis Recommending authority/ association YES N/A non-partner donors all Circumstances for application Donor profile Tissue/cell type Comments Anti-T. pallidum T. pallidum NAT YES N/A partner donors all bacteriology testing of tissues/cells is a requirement for all types of donations Neisseria gonorrhoeae Brucellosis Tuberculosis Q-fever FUNGI Transmissible spongiform encephalopathies Other Tests ABO blood group RhD blood group HLA testing Genetic testing, please specify condition C. trachomatis DFA C. trachomatis EIA C. trachomatis NAT YES N/A all sperm donors except partners Culture sperm mandatory for all sperm donors except partners 6 of 6 2.REPRODUCTIVE T&C 30/06/2016
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding on national level More stringent - recommended on national level Not legy binding and not recommended on
Non-reproductive tissues and cells
Colour key Tested pathogen VIRAL Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recommended on national level Not
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legally binding More stringent - recommended Not legally binding and not recommended Non-reproductive tissues and cells
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Tested pathogen Donor test/ technique
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC and its technical Directives (particularly 2006/17/EC) More stringent -legally binding, applies for all donations and all donor profiles
Non-reproductive tissues and cells
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legally binding on national level More stringent testing - recommended on national level Not legally binding
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent testing - legy binding on national level More stringent testing - recomd on national level Not legy binding and not recomd
Non-reproductive tissues and cells
Ministry of Health: Institute for Transplantation and Biomedicine / Colour key VIRAL HIV 1 and HIV 2 Hepatitis B Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More
Non-reproductive tissues and cells Recommending authority/ association
Colour key Minimum requirements as set out in Directive 2004/23/EC More stringent - legy binding More stringent - recommended Not legy binding and not recommended Non-reproductive tissues and cells VIRAL
Screening donors and donations for transfusion transmissible infectious agents. Alan Kitchen
Screening donors and donations for transfusion transmissible infectious agents Alan Kitchen Aim Not to teach you microbiology To provide and awareness of the big picture To provide an understanding of
Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
Test Name *Minimum Collection Tubes Sample Stability ABO/Rh Blood Typing 50 µl cells EDTA whole blood (lavender-top) Within 14 days at 2-8⁰C. DO NOT FREEZE WHOLE BLOOD Micro Typing Systems 50 µl plasma
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
Schedule of Accreditation 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK National Infection Service, Public Health England Colindale 61 Colindale Avenue London NW9 5EQ Contact: Dr Sanjiv
Directed Semen Donor Eligibility Requirements
Directed Semen Donor Eligibility Requirements Directed (known) reproductive donors using the University Andrology Sperm Banking Program must follow FDA requirements to prevent the transmission of relevant
Structure and duties of Blood service
NATIONAL CENTER FOR TRANSFUSION MEDICINE Prevalence of infectious diseases among Mongolian blood donors Namjil Erdenebayar General director of The National Center for Transfusion Medicine, Mongolia NCTM,
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey
Reporting from Council of Europe member states on the collection, testing and use of blood and blood components in Europe The 2006 Survey This questionnaire consists of three sections: A. Collection and
Controls & Calibrators. Disease Quality Controls
Controls & Calibrators Infectious Disease Quality Controls Infectious Disease Quality Controls A broad selection of controls designed to monitor assay precision of hepatitis, retrovirus, sexually transmitted
Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections.
In the name of God Principles of post Tx infections 1: Potential etiologies of infection in these patients are diverse, including common and uncommon opportunistic infections. Infection processes can progress
EC CERTIFICATE. National Institute for Biological Standards and Control (NIBSC) Blanche Lane South Mimms Potters Bar Hertfordshire EN6 3QG UK
National Institute for Biological Standards and Control (NIBSC) EC Certificate - Full Quality Assurance System Approval Certificate Annex IV (excluding sections 4 and 6) of Council Directive 98/79/EC on
Human tissues and cells annual report 2011
Human tissues and cells annual report 2011 2012 Human tissues and cells Annual report Danish Health and Medicines Authority, 2012. This publication can be freely cited with a clear indication of source.
The Technical Aspects of Pathogen Testing in Canada. Nancy Angus Canadian Blood Services Director, Testing
PERMISSON TO USE: Please note that, by making their presentations available on-line, primary authors have agreed to share their presentations. However, should you want to use some of the data or slides
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING October2010. Issue Summary
TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES ADVISORY COMMITTEE MEETING 28-29October2010 Issue Summary Informational Topic: FDA s Geographic Donor Deferral Policy to Reduce the Possible Risk of Transmission
Egg and Sperm Bank Edinburgh Fertility & Reproductive Endocrine Centre (EFREC) DONOR INFORMATION Screening Tests
Egg and Sperm Bank Edinburgh Fertility & Reproductive Endocrine Centre (EFREC) DONOR INFORMATION Screening Tests Introduction As a potential donor, it is important you are aware of the screening tests
Keeping the Blood Supply Safe Current and Future Strategies. Marissa Li, MD
Keeping the Blood Supply Safe Current and Future Strategies Marissa Li, MD Overview Pre-collection Donor Screening Collection Visual Inspection Aseptic Processing Leukoreduction of Apheresis Collections
Microbiology EQA Product Portfolio
Labquality EQAS Microbiology EQA Product Portfolio Clinically relevant external quality assessment program for microbiology Bacterial serology Bacteriology Mycology Parasitology Preanalytics Virology Labquality
Laboratory diagnostics of blood-borne infections related to blood transfusions and transplantations
26 th Symposium Croatian Society of Medical Biochemistry and Laboratory Medicine Laboratory diagnostics of blood-borne infections related to blood transfusions and transplantations Croatian Institute of
Optimal / Evidence-based Method to Prevent Transmission of Cytomegalovirus (CMV) by Transfusion
ILABB Fall Meeting 2015 Optimal / Evidence-based Method to Prevent Transmission of Cytomegalovirus (CMV) by Transfusion Presenter Ronald G Strauss, MD Associate Medical Director, LifeSource/ITxM Terms
Answering your daily challenges. in the ELISA technology I N FECTI OUS DISEASES. bioelisa
Answering your daily challenges in the ELISA technology I N FECTI OUS DISEASES bioelisa RETROVIRUS HIV is the cause of the most important global pandemic. Due to the lack of vaccination, early diagnosis
Surveillance Report 2014
Surveillance Report 2014 Executive summary We are pleased to present the third report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
CORD BLOOD TRANSPLANTATION STUDY CBU EXCLUSION AND QUARANTINE RELEASE FORM
(Any answer of Yes indicates exclusion) 1. Informed Consent and Maternal/Infant Demographics a. Lack of confirmation of signed and witnessed informed consent 1 Yes 2 No Is the following information missing
The testing of Donated Blood and Components at NHSBT
The testing of Donated Blood and Components at NHSBT NHSBT is responsible for collecting all donated blood and platelets in England, then processing into components before issuing to client hospitals.
Pathogen Reduction/Inactivation KABB Annual Meeting Elpidio Pena, MD, MA Norton Healthcare Transfusion Services
Pathogen Reduction/Inactivation KABB Annual Meeting 2017 Elpidio Pena, MD, MA Norton Healthcare Transfusion Services Goals Discuss the approved methods for pathogen reduction/inactivation of blood products
HEALTH SCREENING QUESTIONNAIRE. Work-up. Donor ID EdgeCell #:
HEALTH SCREENING QUESTIONNAIRE Héma-Québec Registre des Donneurs de Cellules Souches 4045 Côte-vertu, St-Laurent, QC, Canada, H4R 2W7 Tél : + 514-832-1031 Fax : + 514-832-0266 www.hema-quebec.qc.ca CT
Increased Risk Donors. November 1, 2018 BC Kidney Days. Jagbir Gill MD MPH Associate Professor of Medicine UBC
Increased Risk Donors November 1, 2018 BC Kidney Days Jagbir Gill MD MPH Associate Professor of Medicine UBC Median dialysis exposure prior to DDKT Case scenarios Which donors should we accept kidneys
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience
Transfusion transmitted infections in National Haemovigilance Systems: the Greek experience Global blood product safety 10 April 2019, Rome, Italy Constantina Politis National Coordinating Haemovigilance
Laboratory Survey Results. Preventing disease, promoting and protecting health
Laboratory Survey Results Laboratory Survey 211 1 Bacteriology Laboratory Capacity in Twenty (2) CMC Percentage% Capacity 8 6 4 2 Campylobacter Cholera E. coli Leptospirosis N. meningitidis H. influenzae
Immunohistochemical Confirmation of Infections
Immunohistochemical Confirmation of Infections Danny A. Milner, Jr, MD, MSc, FCAP The Brigham and Women s Hospital Harvard Medical School Boston, Masschusetts USA Judicious Use of Immunohistochemistry
DEPARTMENT OF MICROBIOLOGY IMPORTANT NOTICE TO USERS Turnaround Times (TATs) for Microbiology Investigations
Dear User, ISSUE: M008 DEPARTMENT OF MICROBIOLOGY IMPORTANT NOTICE TO USERS Turnaround Times (TATs) for Microbiology Investigations In order to comply with national quality guidance and as part of our
Surveillance Report 2015
Surveillance Report 2015 Executive summary We are pleased to present the fourth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
Increase in Locally-Acquired Cyclosporiasis Cases in Ontario
Increase in Locally-Acquired Cyclosporiasis Cases in Ontario Update to York Region health care providers as of July 31, 2018 Ontario is experiencing an increase in the number of Cyclospora infections.
TRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:
I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related
Case 1. FDA, Legal, and EBAA Medical Standards Panel. Case 1. Case 1 6/25/2012. Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies
Case 1 FDA, Legal, and EBAA Medical Standards Panel Samuel B. Barone, M.D. Office of Cellular, Tissue, and Gene Therapies Medical Directors Symposium Eye Bank Association of America Annual Meeting 47 y/o
Viral hepatitis. Supervised by: Dr.Gaith. presented by: Shaima a & Anas & Ala a
Viral hepatitis Supervised by: Dr.Gaith presented by: Shaima a & Anas & Ala a Etiology Common: Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Less common: Cytomegalovirus EBV Rare: Herpes
2017 CST-Astellas Canadian Transplant Fellows Symposium. Optimizing use of organs from Increased Risk Donors
2017 CST-Astellas Canadian Transplant Fellows Symposium Optimizing use of organs from Increased Risk Donors Atual Humar, MD Atul Humar is a Professor in the Department of Medicine, University of Toronto.
A. Anti-HIV-1/2, HIV NAT Lookback: for those identified blood and blood components collected:
PURPOSE: MATERIALS: To outline a procedure for removing, recalling and/or correcting blood products that do not meet the requirements of the FDA, AABB, or the blood center. Recall/Market Withdrawal Form
Surveillance Report 2016
Surveillance Report 2016 Executive summary We are pleased to present the fifth report for our stakeholders describing infectious disease surveillance. High quality and timely surveillance is key to the
Guidance on Performance Evaluation of In-vitro Diagnostic Medical Devices
Dated:- 07-Aug-2018 Guidance on Performance Evaluation of In-vitro Diagnostic Medical Devices As per the proviso of Clause (h), Paragraph (ii), part II of Fourth Schedule of Medical Devices Rules 2017,
Duration: 12 months May to April
SPECIALIST CERTIFICATE IN TRANSFUSION SCIENCE PRACTICE PROGRAMME OF STUDY OVERVIEW Example only Duration: 12 months May to April This document serves as a general programme overview only. To ensure you
A Transfusion Reaction What Do I Do Now? Judith A. Sullivan, MS, MT(ASCP)SBB, CQA(ASQ) ASCLS Region III Triennial Meeting Birmingham AL
A Transfusion Reaction What Do I Do Now? Judith A. Sullivan, MS, MT(ASCP)SBB, CQA(ASQ) ASCLS Region III Triennial Meeting Birmingham AL This promotional educational activity is brought to you by Ortho
Storage conditions. roomtemperature or incubator at 36 C. Other: 2-8 C Blood: roomtemperature or incubator at. A.s.a.p. max 24h. A.s.a.p.
Extract Vademecum Department of Medical Microbiology Status: Code: Version: Approval date: Geldig MMB-PR-04/1 1 Juni 2017 Name request Specimen Material needed Transport Bacteriology Bacterial culture
Question: 1. Are you currently taking an antibiotic?
Question: 1. Are you currently taking an antibiotic? Donor Eligibility: A donor with an infection that could cause bacteremia/sepsis or other relevant communicable disease should not donate. The reason
Anticipating (re)emerging infections to ensure blood safety
Anticipating (re)emerging infections to ensure blood safety Pierre Tiberghien Etablissement Français du Sang, St-Denis and Université de Franche-Comté, Besançon, France IPFA/PEI 23rd International Workshop
Public Health, Infections and Transplantation
Public Health, Infections and Transplantation Dr Kerry Chant Chief Health Officer & Deputy Director General Population and Public Health NSW Ministry of Health May2014 Public Health Infection and Transplantation
Blood Screening Assays. CTS lab locations where assays are performed are indicated by alpha codes D, P, and T.
Blood Screening Assays CTS lab locations where assays are performed are indicated by alpha codes D, P, and T. D= performed in Dallas lab FEI: 3002580251 P= performed in Phoenix lab FEI: 3000204058 T= performed
For more information about how to cite these materials visit
Author(s): Robertson Davenport, M.D., 2009 License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution Noncommercial Share Alike 3.0 License: http://creativecommons.org/licenses/by-nc-sa/3.0/
We are pleased to present the new Leaflet bioelisa Menu and Instrumentation, with reference
NEWS BK NEWS# 390/ MKT DATE : 13-07-2016 TITLE : New Leaflet bioelisa Menu and Instrumentation Dear colleagues, We are pleased to present the new Leaflet bioelisa Menu and Instrumentation, with reference
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Clinical Microbiology QMC Campus Derby Road Nottingham NG7 2UH Contact: Jil Bowskill Tel: +44 (0) 1905 760192 Ext 30659 E-Mail: jilean.bowskill@nuh.nhs.uk
Mary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital
Transfusion Reactions/Complications Mary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital Acute Transfusion Reactions Can be seen with
Programme Groupings. For 2013, the preliminary molecular external quality assessment (EQA) programme schedule has been displayed by Disease Group.
Equalis EQA s 2013 Preliminary Schedule For 2013, the preliminary molecular external quality assessment (EQA) programme schedule has been displayed by Disease Group. Note: EQA programmes may appear in
Superior Health Council. Reporting and interpreting biological tests carried out on samples from donors of human body material.
Superior Health Council Reporting and interpreting biological tests carried out on samples from donors of human body material. OCTOBer 2016 CSS no. 9314 Superior Health Council Reporting and interpreting
Emerging Pathogens that Impact the Canadian Blood Supply Alberta Vein to Vein Conference March 18-19, 2016
Emerging Pathogens that Impact the Canadian Blood Supply Alberta Vein to Vein Conference March 18-19, 2016 Dr. Margaret Fearon Medical Director, Medical Microbiology, Canadian Blood Services March 18,
FORM TITLE: Risk Behavior Assessment. 1. Are you a male who has had sex with another male in the preceding five years?
RELESE DTE: 12/07/2012 EFFECTIVE DTE: 12/13/2012 1. re you a male who has had sex with another male in the preceding five years? 2. Have you injected drugs for non-medical reason in the preceding five
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies
2014/LSIF/PD/025 Malaysia s Approach to Testing Strategies Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply Chain Manila, Philippines 30 September 1
Sexually Transmitted Infections. Naluce Manuela Morris, MPH, CHES
Sexually Transmitted Infections Naluce Manuela Morris, MPH, CHES Handshake Activity Handshake Activity Mrs. or Mr. X Mrs. or Mr. Y Carry this glove but do not put it on Put this glove on before shaking
Guide to the preparation, use and quality assurance of blood components
Contents Foreword...3 Members of the European Committee (Partial Agreement) on Blood Transfusion... 8 Members of the GTS working group... 22 Members of the TS066 working group... 30 Recommendation No.
+ Intermittent shedding in urine, + Urinary tract
Table 16.3 Examples of s in humans Microorganism Site of persistence Infectiousness of microorganism Viruses Consequence Herpes simplex Dorsal root ganglia Activation, cold sore + Salivary glands + Not
Risk of Other Donor-Derived Infections (nonhiv, nonhcv) Daniel Kaul MD Associate Professor University of Michigan
Risk of Other Donor-Derived Infections (nonhiv, nonhcv) Daniel Kaul MD Associate Professor University of Michigan Conflict of Interest Disclosure I have no relevant financial relationships to disclose
Current Infectious Disease Screening for the Live Organ Donor
2013 Public Health and Safety Guidelines for reducing HIV, HBV and HCV Transmission Though Organ Transplantation: Implications for Counseling and Disclosure Dianne LaPointe Rudow DNP, ANP-BC, CCTC Director
10/17/2015. Chapter 55. Care of the Patient with HIV/AIDS. History of HIV. HIV Modes of Transmission
Chapter 55 Care of the Patient with HIV/AIDS All items and derived items 2015, 2011, 2006 by Mosby, Inc., an imprint of Elsevier Inc. All rights reserved. History of HIV Remains somewhat obscure The earlier
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS APRIL 2017 Infectious viruses are a global health threat Since the approval of the first antiviral drug
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 39, 2018 (Notification
Increased Risk Donors for Organ Transplantation
A Tool Kit to Assist Transplant Programs in the Use of Increased Risk Donors for Organ Transplantation February 2016 Table of Contents Table of Contents... 2 1.0 Increased Risk Donor Tool Kit... 3 1.1
L 256/32 Official Journal of the European Union
L 256/32 Official Journal of the European Union 1.10.2005 COMMISSION DIRECTIVE 2005/61/EC of 30 September 2005 implementing Directive 2002/98/EC of the European Parliament and of the Council as regards
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS
Image of Ebola viruses exiting host cells HUMAN VIRUSES & THE LIMITATION OF ANTIVIRAL DRUG AGENTS MAY 2017 1 Infectious viral pathogens are a significant global health threat to mankind 2 Since the approval
Keeping blood transfusions safe:
ISP-WIV Seminar Diagnosis and surveillance of infectious diseases May 18 th, 2017 Keeping blood transfusions safe: the challenge of emerging infectious diseases Presented by Roland HÜBNER Superior Health
Database on Blood Safety 2009 in ECO Member States
Database on Blood Safety 2009 in ECO Member States Section 1: Administrative Information Information provided by: 1.1 Name: 1.2 Title: 1.3 Position: 1.4 Organization: 1.5 Address: 1.6 Country: 1.7 Tel.
COMMUNICABLE DISEASE REPORT
June 2011 Department of Health and Community Services Government of Newfoundland and Labrador COMMUNICABLE DISEASE REPORT Reporting Sexually Transmitted and Bloodborne Infections All laboratory-confirmed
Perform Gram stain only. Select Survey D5, Gram Stain
www.cap.org Bacteriology This flowchart is provided as a guide for ordering the appropriate Bacteriology Surveys for your laboratory s testing menu. In order to meet CLIA requirements for the subspecialty
MOLECULAR DIAGNOSTIC PANELS and REAGENT KITS for NUCLEIC ACID EXTRACTION and RT-PCR of INFECTIOUS DISEASES and GENOMICS. Sep 2018
MOLECULAR DIAGNOSTIC PANELS and REAGENT KITS for NUCLEIC ACID EXTRACTION and RT-PCR of INFECTIOUS DISEASES and GENOMICS Sep 2018 STANDARDISED & EASY APPROACH TO PCR DIAGNOSTICS The diagnostic kits of MOLgen
Transfusion Medicine (Comprehensive, Limited) J, J1
www.cap.org Transfusion Medicine Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Transfusion Medicine (Comprehensive, Limited)
HEALTH SCREENING QUESTIONNAIRE CT Work-up. Donor ID EdgeCell #:
HEALTH SCREENING QUESTIONNAIRE CT Work-up Héma-Québec Registre des Donneurs de Cellules Souches 4045 Côte-vertu, St-Laurent, QC, Canada, H4R 2W7 Tél : + 514-832-1031 Fax : + 514-832-0266 www.hema-quebec.qc.ca
Table of Contents (continued)
Emerging Molecular and Immunohematology Blood Typing, Grouping And Infectious Disease NAT Screening Assays And Companies Developing New Technologies and Products Table of Contents 1. Blood Typing and Grouping
Question: 1. Are you currently taking an antibiotic?
Question: 1. Are you currently taking an antibiotic? Donor Eligibility: A donor with an infection that could cause bacteremia/sepsis or other relevant communicable disease should not donate. The reason
HEPATITIS B AND HEPATITIS C VIRUS AMONG BLOOD DONORS
HEPATITIS B AND HEPATITIS C VIRUS AMONG BLOOD DONORS VIRAL HEPATITIS PREVENTION BOARD MEETING LISBON, PORTUGAL, 18 19 November 2010 Gabriel de Olim Presidente do Conselho Directivo do Instituto Português
The New Regulations - Special IVD Issues
The New Regulations - Special IVD Issues Dirk Stynen, Ph. D. President - Principal Consultant Qarad Geel, Belgium RMD Brussels October 2018 The IVD Regulation 2017/746 October 29, 2018 www.qarad.com 2
Risky Business Preventing Disease Transmission From Donor Organs. Peter Chin-Hong, MD UCSF September 2012
Risky Business Preventing Disease Transmission From Donor Organs Peter Chin-Hong, MD UCSF September 2012 Case 1: Something rare? 54 yo WM with HBV/HCV/HCC Day 5: Fever to 102.4, mild frontal HA since time
Manitoba Monthly Surveillance Unit Report
Manitoba Monthly Surveillance Unit Report Reported up to June 30, 2012 Highlights: 1. Antimicrobial Resistant Organisms Together Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile
Sexually Transmi/ed Diseases
Sexually Transmi/ed Diseases Chapter Fourteen 2013 McGraw-Hill Higher Education. All rights reserved. Also known as sexually transmitted infections The Major STDs (STIs) HIV/AIDS Chlamydia Gonorrhea Human
Telephone: Téléphone : Fax: Télécopieur :
Health Santé Health and Healthy Living Santé et Vie saine Public Health Division Division de la santé publique Communicable Disease Control Branch Prévention des maladies transmissibles Fourth Floor, 300
Draft Agreed by Biologics Working Party December Draft Agreed by Blood Products Working party December 2010
15 December 2011 EMA/CHMP/BWP/360642/2010 rev. 1 Committee for Medicinal Products for Human Use (CHMP) Guideline on the warning on transmissible agents in summary of product characteristics (SmPCs) and
The Study of Congenital Infections. A/Prof. William Rawlinson Dr. Sian Munro
The Study of Congenital Infections A/Prof. William Rawlinson Dr. Sian Munro Current Studies SCIP Study of Cytomegalovirus (CMV) Infection in Pregnancy ASCI Amniotic Fluid Study of Congenital Infections
CHAPTER 1: SEXUALLY TRANSMITTED AND BLOODBORNE INFECTIONS
CHAPTER : SEXUALLY TRANSMITTED AND BLOODBORNE INFECTIONS Highlights In Peel, the incidence of Acquired Immunodeficiency Syndrome (AIDS) has remained low (. to. cases per,) since the introduction of the
Hot Topics in Tissue Safety
Hot Topics in Tissue Safety 37 th Annual AATB Meeting National Harbor, Maryland 03 October 2013 Scott A. Brubaker, CTBS Chief Policy Officer PHS Guideline for Reducing Human Immunodeficiency Virus, Hepatitis
CONTACTS & ACKNOWLEDGEMENTS
CONTACTS & ACKNOWLEDGEMENTS Snohomish Health District Communicable Disease Surveillance and Response Analysis and publication: Hollianne Bruce, MPH Program Manager: Amy Blanchard, RN, BSN Communicable
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 50, 2018 (Notification
United Kingdom National External Quality Assessment Service for Microbiology [Established 1971]
![United Kingdom National External Quality Assessment Service for Microbiology [Established 1971]](/thumbs/95/123501270.jpg "United Kingdom National External Quality Assessment Service for Microbiology [Established 1971]")
United Kingdom National External Quality Assessment Service for Microbiology [Established 97] UK NEQAS covers Andrology Chemistry Genetics Haematology Histopathology Immunology Leucocyte Immunophenotyping
There is an erythrocyte agglutination event based on antigen-antibody relationships.
BLOOD GROUPS There is an erythrocyte agglutination event based on antigen-antibody relationships. Antibodies are present in serum. In blood, the serum is the component that is neither a blood cell (serum
Infectious Disease Controls for Serology Testing
Infectious Disease Controls Infectious Disease Controls for Serology Testing A comprehensive guide for monitoring testing for Hepatitis, Retrovirus, Sexually Transmitted and Congenital Diseases Table of
HPSC - Weekly Infectious Disease Report
HPSC - Weekly Infectious Disease Report Statutory Notifications of Infectious Diseases reported in Ireland via the Computerised Infectious Disease Reporting (CIDR) system for: Week 38, 2018 (Notification
DS-EIA-ANTI-HIV-UNIF (Ab) I DS-EIA-ANTI-HIV-UNIF (Ab) I DS-EIA-ANTI-HIV-UNIF (Ab) I
* Sensitivity HIV DS-EIA-ANTI-HIV-UNIF (Ab) I-153 96 115 24 DS-EIA-ANTI-HIV-UNIF (Ab) I-150 192 115 24 DS-EIA-ANTI-HIV-UNIF (Ab) I-155 480 115 24 DS-EIA-HIV-AG-SCREEN I-1452 96 115 12 0.025 IU/ml DS-EIA-HIV-AGAB-SCREEN
Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Royal Liverpool & Broadgreen University Hospitals NHS Trust Department of Virology Liverpool Clinical Laboratories Royal Liverpool and Broadgreen